tadocizumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470476685

| type = mab

| mab_type = Fab

| source = zu/o

| target = Integrin α_IIbβ₃

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 339086-80-5

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R34T642CGV

| C=2107 | H=3252 | N=562 | O=673 | S=12

}}

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[http://www.ama-assn.org/ama1/pub/upload/mm/365/tadocizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab], American Medical Association. It binds to integrin α_IIbβ₃, a fibrinogen and fibronectin receptor found on platelets.

{{cite book | vauthors = Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky L, Darnell J |title=Molecular cell biology |date=2003 |publisher=W.H. Freeman |location=New York |isbn=978-0-7167-4366-8 |edition=5th | page = 973 }} The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.